hangzhou tigermed consulti-a
(300347:Shenzhen Stock Exchange)
Transactions by HANGZHOU TIGERMED CONSULTI-A (300347) in the last 6 months
Hangzhou Tigermed Consulting Co., Ltd. (SZSE:300347) signed letter of intent to acquire 70% stake in DreamCIS, Inc. from Leenos Corp. (KOSDAQ:A039980) for KRW 27 billion on June 6, 2015. A total of 0.07 shares will be acquired as part of this transaction. Expected closing is on October 12, 2015.
Hangzhou Tigermed Consulting Co., Ltd. (SZSE:300347) agreed to acquire 98.14% stake in DreamCIS, Inc. from Leenos Corp. (KOSDAQ:A039980) and Won-Young Choi for KRW 32.2 billion ...
Walvax Biotechnology Co.,Ltd (SZSE:300142), Hangzhou Tigermed Consulting Co., Ltd. (SZSE:300347), Sinkiang-based equity investment company and other investors signed an equity acquisition agreement to acquire a 54% stake in Taizhou Jietong Tairui Pharmaceutical Technology Co., Ltd. from Xinjiang Tairui Equity Investment Partnership, Fu Xiaoyang and another individual on April 8, 2015. The acquisition will be made through a newly established fund with a registration capital ...
Walvax Biotechnology Co.,Ltd
|PAREXEL International Corp||$64.09 USD||-0.46|
|WuXi PharmaTech Cayman Inc||$42.37 USD||+0.05|
|View Industry Companies|